BiotechTube

SPN-538 + Placebo

ApprovedTerminated
0 watching 0 views this week🔥 Hot
80
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Migraine Disorders

Conditions

Migraine Disorders, Headache Disorders

Trial Timeline

Jul 14, 2020 → Mar 1, 2023

NCT ID
NCT04050293

About SPN-538 + Placebo

SPN-538 + Placebo is a approved stage product being developed by Supernus Pharmaceuticals for Migraine Disorders. The current trial status is terminated. This product is registered under clinical trial identifier NCT04050293. Target conditions include Migraine Disorders, Headache Disorders.

Hype Score Breakdown

Clinical
30
Activity
20
Company
5
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT04050293ApprovedTerminated

Competing Products

20 competing products in Migraine Disorders

See all competitors
ProductCompanyStageHype Score
ABP-450AEON BiopharmaPhase 2
44
Lasmiditan + PlaceboEli LillyPhase 3
77
Placebo + LY2300559Eli LillyPhase 2
52
lasmiditan 200 mg + Sumatriptan + matching placeboEli LillyPhase 1
33
ABP-450 + PlaceboAEON BiopharmaPhase 2
44
Lasmiditan + PlaceboEli LillyPhase 2
52
Ketorolac + Prochlorperazine + DiphenhydramineAssertio HoldingsPhase 2
44
Galcanezumab + ErenumabEli LillyApproved
85
Aricept (donepezil hydrochloride)EisaiPhase 2
52
E2007EisaiPhase 2
52
Galcanezumab + Rimegepant + Placebo + PlaceboEli LillyApproved
85
Galcanezumab + PlaceboEli LillyPhase 3
77
Lasmiditan + PlaceboEli LillyPhase 2
52
Galcanezumab + PlaceboEli LillyPhase 3
77
LasmiditanEli LillyPhase 3
77
Galcanezumab Prefilled Syringe + PlaceboEli LillyPhase 2
52
Emgality 120 MG in 1 ML Prefilled SyringeEli LillyApproved
85
GalcanezumabEli LillyPre-clinical
23
Galcanezumab + PlaceboEli LillyPhase 3
77
Galcanezumab + PlaceboEli LillyPhase 2
52

Other Products from Supernus Pharmaceuticals

ZULRESSO®Approved
80
APOKYNApproved
80
SPN-812Approved
80
SPN-812Approved
80
100mg SPN-812 + PlaceboApproved
80